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Abstract
Background:  The ability of cytosine deaminase (CD) to convert the antifungal agent 5-
fluorocytosine (5-FC) into one of the most potent and largely used anticancer compound such as
5-fluorouracil (5-FU) raised considerable interest in this enzyme to model gene or antibody –
directed enzyme-prodrug therapy (GDEPT/ADEPT) aiming to improve the therapeutic ratio
(benefit versus toxic side-effects) of cancer chemotherapy. The selection and characterization of a
human monoclonal antibody in single chain fragment (scFv) format represents a powerful reagent
to allow in in vitro and in vivo detection of CD expression in GDEPT/ADEPT studies.
Results: An enzymatic active recombinant CD from yeast (yCD) was expressed in E. coli system
and used as antigen for biopanning approach of the large semi-synthetic ETH-2 antibody phage
library. Several scFvs were isolated and specificity towards yCD was confirmed by Western blot
and ELISA. Further, biochemical and functional investigations demonstrated that the binding of
specific scFv with yCD did not interfere with the activity of the enzyme in converting 5-FC into 5-
FU.
Conclusion: The construction of libraries of recombinant antibody fragments that are displayed
on the surface of filamentous phage, and the selection of phage antibodies against target antigens,
have become an important biotechnological tool in generating new monoclonal antibodies for
research and clinical applications. The scFvH5 generated by this method is the first human antibody
which is able to detect yCD in routinary laboratory techniques without interfering with its
enzymatic function.
Background
The ability of cytosine deaminase (CD) to convert the
clinically used antifungal agent 5-fluorocytosine (5-FC)
into one of the most potent and largely used anticancer
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agent such as 5-fluorouracil (5-FU) raised considerable
interest in this enzyme to design innovative anticancer
therapies [1,2]. Therefore, CD-based enzyme/prodrug
strategies are under investigation to model gene or anti-
body directed enzyme-prodrug therapy (GDEPT/ADEPT)
for achieving high local concentration of 5-FU without
significant systemic toxicity [3,4]. In in vivo animal
model, the CD gene/enzyme which is not naturally
expressed in mammals are first introduced into the cells of
a tumour by specific antibodies [5-7], modified microor-
ganisms such as bacteria and viruses or synthetic vectors
(reviewed by Springer et al., 2007)[4]. When the discrim-
ination between tumor and normal tissue enzyme levels is
sufficient, 5-FC is given i.v., which is converted into 5-FU
by CD within the tumor [8]. A convincing demonstration
that such a complex system can be developed for clinical
use requires evidence that each of the components of the
gene/antibody complex functions by the mechanisms
proposed [9]. This can be provided by well defined meas-
urements including the concentration levels of the anti-
body-enzyme conjugate or de novo expressed enzyme, in
plasma, tumor and normal tissues [10-12]. To allow the
detection of CD expression at the protein level, we raised
a human monoclonal antibody in single chain fragment
(scFv) format against a recombinant CD from yeast (yCD)
proved to be functionally active in NMR and in in vitro
studies to convert the antifungal drug 5-FC into the anti-
cancer compound 5-FU. The specificity of the human scFv
was confirmed by Western blot and ELISA analyses. With
this antibody, yCD expression can now be monitored
without interfering with its enzymatic function in GDEPT,
ADEPT and other studies leading to the effect of the so
called tumour amplified protein expression and targeting
(TAPET) to localize in vitro and in vivo generation of the
anticancer agent 5-FU [4].
Results and discussion
The CD/5-FC-based GDEPT or ADEPT are among the
most studied strategies aiming to improve the therapeutic
ratio (benefit versus toxic side-effects) of cancer chemo-
therapy. CD has the ability to deaminate the non toxic
prodrug 5-FC into the highly toxic compound 5-FU. By
inhibiting DNA synthesis this drug preferentially kills
tumour cells. However, 5-FU has high gastrointestinal and
hematological toxicities [2]. In contrast, the prodrug 5-FC
is fairly nontoxic [13]. and CD is not naturally expressed
in mammalian cells. Thus, the selectively guided CD/5-FC
complex should minimize the toxic effects of 5-FU
because the conversion of 5-FC to 5-FU should only occur
within the tumor.
A convincing demonstration that this strategy can be
developed for clinical use requires knowledge of specific
parameters which may include the in in vivo monitoring
of the CD complex. For this reason we have firstly con-
structed a novel expression system for the production of a
functionally active yCD. Subsequently a fully human anti-
body in scFv format not interfering with yCD activity was
developed and analyzed.
Expression and purification of yCD protein
A functionally active yCD was generated by recombinant
DNA technology. The gene encoding for yCD was ampli-
fied and inserted into the pQE30Xa expression vector
which contained the lac promoter for protein induction
and 6 × His TAG sequence for purification (Fig. 1A). 500
base pairs band shown in Figure 1B corresponded to DNA
fragment encoding for yCD obtained by PCR using spe-
cific primers. After TG1 E. coli bacterial strain transforma-
tion, several clones were isolated and proved suitable for
yCD production. The clone exhibiting the best protein
induction was further characterized. The yield of purified
protein was about 10 mg l-1, using metal chelate affinity
chromatography. The reliability of this novel expression
system used for protein isolation and purification was
confirmed by biochemical investigation showing that
yCD migrated at the expected molecular weight of about
20 kDa (Figure 1C).
Selection and characterization of scFvH5 antibody specific 
for yCD
To isolate phage-displayed specific antibodies, an aliquot
of the human synthetic ETH-2 library containing approx-
imately 1 × 1012 cfu phages was panned into Nunc-immu-
notubes coated with 10 μg ml-1of purified yCD. Non-
specifically absorbed phages were removed by intensive
washing. Specific bound phages were eluted, amplified
and used for next panning as previously described [14]. By
using this protocol, we were able to isolate a phage-anti-
body population specifically recognizing yCD protein
after only three rounds of selection. Plating on agar of TG1
cells infected with a pool of phage antibodies from third
selection allowed individual clones harboring phagemid
to grow. Soluble scFvs derived from IPTG inducted colo-
nies, were screened by ELISA and several of them proved
to be specific for yCD protein (Figure 2). One of the most
reactive scFv antibody clone, named H5, was isolated and
further characterized under biochemical and genetic
aspects.
Western blot studies showed that scFvH5 recognizes a
protein band of about 20 KDa corresponding to the
expected molecular weight of the purified yCD protein
(see Fig. 2, inserted box). The genes encoding for variable
regions of heavy (VH) and light (VL) chains of the scFvH5
were sequenced, and their corresponding amino acid
aligned (Fig. 3) according to Pini et al., [15].BMC Biotechnology 2008, 8:68 http://www.biomedcentral.com/1472-6750/8/68
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Expression of recombinant yCD Figure 1
Expression of recombinant yCD. In (A), is depicted a schematic representation of yCD expression vector, constructed by 
inserting the coding sequence for yCD into pQE30Xa plasmid, and expressed in TG1 strain of E. coli. In (B) and (C) are shown 
respectively, the PCR-DNA fragment corresponding to the expected 500 bases pair encoding for yCD and the immuno-blot of 
the purified yCD protein.
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Determination of yCD activity
In order to determine the functional activity of the recom-
binant yCD, the ability of the enzyme to deaminate 5-FC
was assessed by fluorine NMR. This approach allowed
simultaneous detection of the substrate and the product
without interference by other compounds. Figure 4 shows
that after 90 min 5-FC was completely converted into 5-
FU in the presence of the yCD. Absolute quantification of
the product was obtained by adding a known amount of
5-FU to the reaction mixture at the end of the experiment.
The specific yCD enzymatic activity was also assessed by
spectrophotometric analysis in order to determine
nanomolar concentrations of the reaction product. Figure
5A shows the initial velocity of the reaction which is rep-
resented by direction coefficient of the line plotted plac-
ing concentration of formed 5-FU versus reaction time.
In order to assess if the enzymatic activity of yCD was
affected by the presence of the scFvH5 an identical exper-
iment was performed in presence of the antibody. Figure
5B shows that the rate of product formation was similar to
that with free yCD, suggesting that there was no apparent
loss in enzyme activity as a result of binding with scFvH5.
Identical results were obtained using the irrelevant
scFvGO antibody (see Figure 5C).
Cytotoxic assay
Using an in vitro model constituted by human LoVo cells,
we measured the enzymatic activity of the recombinant
yCD protein in converting the antifungal agent 5-FC into
the highly toxic anticancer compound 5-FU. In parallel we
evaluated if co-incubation of the same reagents with
scFvH5 affected yCD function. Figure 6A shows that 2.5
μg ml-1 of yCD exerted a significative cell growth inhibi-
tion of the human carcinoma LoVo cells in the presence of
5-FC concentration ranging from 1 mg ml-1 and 10 μg ml-
1. In contrast, the co-incubation of yCD and 5-FC with var-
ious concentration of scFvH5 did not interfere with the
cytotoxic activity of de novo generated 5-FU (Figure 6B).
Selection of yCD-specific scFvs Figure 2
Selection of yCD-specific scFvs. IPTG inducted bacterial supernatants of individual colonies from the third round of the 
ETH-2 selection on yCD protein, were tested by ELISA in 96-well microtiter plates coated with the antigen. OD values higher 
than three fold the value of negative control are scored as positive. Negative and positive controls positioned in wells 1–4 
reacted as expected. In the inserted box, the Western blot of yCD protein detected by scFvH5 (one of the most reactive 
clones) is shown.
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The results above reported demonstrated that, yCD pro-
duced by the novel expression system here described acts
as an active enzyme in converting 5-FC into the anticancer
compound 5-FU. Moreover, the binding of the human
scFvH5 with yCD did not affect the enzyme function. In
particular, our studies demonstrated that the presence of
scFvH5 did not interfere with yCD in converting 5-FC or
with the cytotoxic activity of de novo formed 5-FU.
Sequence analysis of scFv H5 and genetic structure of phage antibody from ETH-2 library Figure 3
Sequence analysis of scFv H5 and genetic structure of phage antibody from ETH-2 library. The amino acid 
sequence of the CDR3 regions of the selected scFv H5 antibody are reported. A schematic representation of the scFv antibod-
ies dislpayed on M13 phage as pIII fusion proteins is depicted.
lac p pelB gene III
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Functional analysis of yCD by 19F NMR study Figure 4
Functional analysis of yCD by 19F NMR study. In (A) and (B) are shown respectively, the 5-FU formation (μlmoles) due 
to the conversion of 5-FC by yCD and representative spectra during the reaction at 20, 39, 63 and 80 min.
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Conclusion
The monoclonal antibody scFvH5 may be a very useful
reagent for detection of CD expression in GDEPT/ADEPT
studies. In fact, this mAb detects functional yCD either in
ELISA or in Western blot studies (Figure 1 and 2) thus pro-
viding evidence that similar techniques may be extended
to measure yCD levels in plasma, tumor and normal tis-
sue samples. Since its particular genetic origin, the scFvH5
can be easily genetically engineered to construct a whole
human antibody with a predefined IgG subclass, for selec-
tive removal of mAb-yCD conjugate from the circulation,
without interfering with the enzyme function.
Differently with other mAbs to CD generated by hybrid-
oma [5] or recombinant DNA technologies [16], the
scFvH5 is the first fully human monoclonal antibody in
scFv format so far described which is able to detect yCD
protein in different routinary laboratory techniques.
Hence, this antibody may represents an excellent candi-
date for in vivo detection and measurement of the CD
complex in the future development of CD-based selec-
tively guided tumor therapy.
Methods
Antibodies and reagents
The characteristics of the scFvGO used in this study as scFv
irrelevant antibody were previously described [17]. Anti-
Flag M2 and anti-polyhistidine antibodies were pur-
chased from Sigma (St Louis, MO, USA). The goat anti-
mouse HRP-conjugated polyclonal antibody was pur-
Spectrophotometry of yCD activity Figure 5
Spectrophotometry of yCD activity. In (A), are reported the values of de novo formed 5-FU (mM) obtained in presence 
of yCD (0.5 μg ml-1) and 5-FC (0.18 mM) during the first 9 min of the reaction. In (B) and (C) are reported the 5-FU values 
obtained with identical reagents but in presence of 2 μg ml-1 of the specific (scFvH5) or irrelevant (scFvGO) antibodies. Slope 
of lines represents starting speed of the reaction. Correlation coefficient (R) indicates the strength and direction of the linear 
relationship between time and formed 5-FU.
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chased from Dako (Denmark, EU). 5-Fluorocytosine (5-
FC) and 5-Fluorouracil (5-FU) were purchased respec-
tively, from Sigma and Mayne Pharma (Naples, Italy, EU)
Vector construction
Complete yCD gene sequence [18] was amplified by PCR
from cDNA inserted in pACCMV 115. The sense primer
was: BamyCD 5'-CGA ATT GGA TCC ATG GTG ACA GGG
GGA-3', containing BamHI restriction site and the
sequence coding for first five amino acid of yCD. The anti-
sense primer was: ESyCD 5'-ATCC GAT ATC GTC GAC
CTC ACC AAT ATC TTC-3' containing the sequences
encoding for the end part of yCD and SalI restriction
enzyme.
PCR was performed using Pwo enzyme (Roche Diagnos-
tics; IN, USA) and the resulting PCR fragment was agar-
ose-purified using the High Pure PCR Product Purification
Kit (Roche). Then it was digested with restriction enzymes
BamHI and SalI, and cloned into the plasmid pQE30Xa
(Qiagen; Milan, Italy, EU), containing 6 × His tag
sequence for protein purification. The clone was
sequenced by Biofab Research SRL (Rome, Italy, EU).
Expression and purification
TG1 E. coli (supE hsdΔ5 thi Δ(lac-proAB) F' [traD36 proAB+
lacIqlacZΔM15]) cells trasformed with plasmid pQE30Xa
yCD were grown in 100 ml 2 × TY broth supplemented
with 100 μg ml-1 ampicillin and 0.1% glucose in a 37°C
shaker until OD600 = 0.6. Isopropyl-β-D-thiogalactopyra-
noside (IPTG) (Sigma) was added to a final concentration
of 1 mM. Cells were harvested 3 h later, centrifuged at
10,000 rpm for 20 min at 4°C and lysed by sonication in
lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole, pH 8). The yCD protein was purified by affin-
ity chromatography on Ni-NTA resin (Qiagen), using
native protocol according to the manufacture instruc-
tions. Protein concentration was determined with Fernan-
dez-Patron method. The purified yCD protein was
dissolved in PBS, aliquoted and stored at -80°C.
NMR
19F NMR analyses were performed on BRUKER AVANCE
spectrometer (Bruker BioSpin GmbH – Rheinstetten –
Germany) operating at 9.4 T. The spectra were acquired at
25°C with a pulse angle of 60°, interpulse delay of 2 s and
64 transients. In order to compensate for partial magnetic
saturation effect, the correction factors were determined
by comparing the measured peak areas with those
obtained at equilibrium (flip angle 90°, interpulse delay
30 s). At the end of reaction the concentration of 5-FU was
determined by adding a known amount of the drug. Spec-
tral analyses were performed utilizing the XWIN-NMR
BRUKER suite. 19F-MRS of 3,5 μmoles of 5-FC dissolved in
700 ul D2O saline buffer was considered the time 0 of the
reaction and after 70 μl of 25 μg/ml yCD enzyme were
In in vivo assay of yCD protein Figure 6
In in vivo assay of yCD protein. In (A), LoVo cells were seeded in 96-well plate (2500 cells/well) and cultured in BM for 4 
days containing 2.5 μg ml-1 of yCD in presence of the indicated concentrations of 5-FC. In (B), the cells were culture at same 
conditions but in BM containing 2.5 μg ml-1 of yCD and 10 μg ml-1 of 5-FC in presence of different concentrations of scFvH5 or 
the irrelevant scFvGO antibodies. Cell cytotoxicity (due to de novo formed 5-FU) was evaluated by WST-1 assay and calculated 
as a percentage of survived cells. Values are reported as the mean of triplicate samples. The bars indicate SD.
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added. The reaction was followed during 1 h and 30 min.
To verify the complete conversion of 5-FC to 5-FU the last
spectrum was acquired at 3 h and 15 min.
ETH-2 library
The ETH-2 synthetic human recombinant antibodies
library consists of a large array (more than 109 antibody
combination) of scFv polypeptides displayed on the sur-
face of M13 phage [14]. It was built by random mutagen-
esis of the CDR3 of only three antibody germline gene
segments (DP47 for the heavy chain, DPK22 and DPL16
for the light chain). Diversity of the heavy chain was cre-
ated by randomizing four to six position, replacing the
pre-existing position 95–98 of the CDR3. The diversity of
the light chain was created by randomizing six position
(96–101) in the CDR3 [15].
Selection of yCD protein specific antibodies from ETH-2 
library
Immunotubes (Nalge Nunc International; NY, US) were
coated overnight (ON) at room temperature (RT) with
purified yCD in PBS at the concentration of 10 μg ml-1.
After panning, performed according to Ascione et al. [17],
phages were eluted with 1 ml of 100 mM triethylamine,
and the solution was immediately neutralized by adding
0.5 ml of 1 M Tris-HCl pH 7.4. Eluted phages were used
to infect TG1 E. Coli cells and amplified for the next round
of selection. Briefly, 50 ml of 2 × TY with 100 μg/ml amp-
icillin and 1% glucose (2 × TY-amp-glu) were inoculated
with enough bacterial suspension to yield an OD600 nm ≅
0.1. The culture was grown to OD600 nm = 0.4–0.5 and
infected with K07 helper phage at a ratio of around 20:1
phage/bacteria. The rescued phages were concentrated by
precipitation with PEG 6000 and used for the next round
of panning. For soluble scFv preparation, cloned E. coli
cells were grown for 2 h at 37°C in 180 μl of 2 × TY-amp-
icillin (100 μg ml-1) and 0.1% glucose in 96-well plates
and induced with 50 μl of 2 × TY-6 mM IPTG. The follow-
ing day the plates were spun down at 1800 g for 10 min at
4°C and the supernatants containing soluble scFv were
recovered and tested for specific yCD recognition in
ELISA.
ELISA
96-well ELISA plates were coated ON with 50 μl/well of
10 μg ml-1 purified yCD in PBS at 4°C. Next day a block-
ing solution, 2% non-fat milk in PBS (2% MPBS) was
added and after 2 h the plates were washed with PBS con-
taining 0.05% Tween 20 (TPBS). Plates were incubated for
2 h at RT with 50 μl of supernatants containing soluble
scFv antibodies, anti-Flag M2 antibody and anti-mouse
HRP-conjugated antibody. All antibodies were resus-
pended in 2% MPBS.
The reaction was developed using 3,3'-5,5'-tetramethyl-
benzidin BM blue and POD substrate soluble (Roche
Diagnostics) and stopped by adding 50 μl of 1 M sulfidric
acid. The reaction was detected with an ELISA reader
(BIORAD; CA, USA) and the results were expressed as OD,
i.e. the absorbance per unit length, were absorbance (A) is
calculated as A = A (450 nm) – A (620 nm).
DNA characterization and sequences
Plsmidic DNA encoding for selected scFvs were digested
by specific endonucleases and CDR3 regions were
sequenced with an automated DNA sequencer (M-Medi-
cal/Genenco, Pomezia Italy) using fdseq1 (5'-GAA TTT
TCT GTA TGA GG-3') and pelBback (5'-AGC CGC TGG
ATT GTT ATT AC-3') primers.
Soluble scFv purification
The clone scFvH5, was cultured for large-scale scFv pro-
duction. TG1 E. coli infected cells were cultured at 30°C in
2 × TY containing 100 μg ml-1 ampicillin and 0.1% glu-
cose up to OD600  = 0.5. After induction of antibody
expression by adding 1 mM IPTG to culture, cells were
incubated ON at 30°C. Then, the bacterial culture was
centrifugated and antibody containing supernatant col-
lected. Antibody fragments were precipitated with ammo-
nium sulfate and dialyzed in PBS. His-tagged scFv
fragments were purified by immobilized metal affinity
chromatography using Ni2+-nitriloacetic acid agarose
(Qiagen). ScFv fragments were eluted with 250 mM imi-
dazole in PBS, dialyzed, ELISA tested for specific antigen
recognition, and stored at -80°C.
SDS-PAGE and Western Blot analysis
Purified yCD protein was analyzed on 12% SDS PAGE gel
under reducing conditions. Gel was either stained with
Fernandez-Patron method or blotted electrophoretically
to nitrocellulose membrane, which was blocked in 5%
MPBS and then washed three times for 10 min in PBS. For
detection of yCD protein, the membrane was incubated
either with anti-polyhistidine antibody or with soluble
scFvH5. In the first case the membrane was incubated for
2 h with anti-polyhistidine antibody 1:1000 in 2% M/PBS
and washed three times with PBS. In the other, the mem-
brane was incubated for 2 h with soluble scFvs, washed
with PBS containing 0.05% Tween 20 and incubated
again with an anti-Flag M2 mouse antibody 1:1000 in 2%
MPBS for 1 h at RT. In both cases specific binding was
detected by HRP-conjugated Goat anti-mouse antibody
1:1000 in M/PBS 2% for l h at RT. After 3 washings in 2%
M/PBS, the bound antibodies were visualized with DAB
buffer obtained by dissolving one tabelet (10 mg) of 3,3'-
diaminobenzidine (Sigma) in 20 ml of PBS and 3 μl of
hydrogen peroxide 30%, for 3 min. The reaction was
stopped with H2O.BMC Biotechnology 2008, 8:68 http://www.biomedcentral.com/1472-6750/8/68
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Determination of yCD activity
The deamination activity of purified yCD was measured
by monitoring conversion of 5-FC to 5-FU in spectropho-
tometric studies. In 0.5 ml quartz cuvette, 250 μl of 1 μg
ml-1 yCD was added to solution of 0.36 mM of 5-FC. The
reaction was followed for 30 min by an UV/Vis spectro-
photometer (Beckman DU-64, Beckman Coulter S.p.A.,
CA, USA) which registered absorbance values every 30
seconds. The absorbance variation was measured at 265
nm, wavelength of the 5-FU maximum UV absorption
according to Nishiyama et al., 1985 [17]. Absorbance val-
ues were calculated as A265 (t) - A265 (t0), (t0 = 0 min); the
values were converted in concentration of formed 5-FU,
dividing absorbance values by 5-FU molar extinction coef-
ficient at 265 nm (ε265). The calculated 5-FU ε265 was 7
mM-1 cm-1. Initial velocity of the enzyme was calculated as
ΔA265 min-1 or as Δ[5-FU] min-1in the first 9 min when the
reaction had linear trend.
The same procedures were used in order to examine even-
tual inhibition of yCD activity occurred in presence of
scFvH5. Briefly, 5 μl of 200 μg ml-1 purified scFvH5 solu-
tion were added into the cuvette with yCD and 5-FC. Par-
allel experiments were performed in presence of the
irrilevant scFvGO antibody.
Cytotoxic assay
The ability of purified yCD protein to convert 5-FC into 5-
FU was tested in an vitro cell sytem. The human colon
adenocarcinoma LoVo cells were maintained in a basic
medium (BM) constituted by RPMI 1640 (EuroClone
S.p.A; PV, Italy, EU) supplemented with 10% fetal bovine
serum (EuroClone) and 1% penicillin-streptomycin in
humidified atmosphere with 5% CO2 at 37°C.
In a cell growth inhibition assay 2500 cells/well were
seeded into 96-well microtiter plates (Corning Cable Sys-
tems SRL, Turin, Italy, EU) in BM containing 2.5 μg ml-1
of yCD and different concentrations of 5-FC. The plates
were incubated at 37°C for 4 days and cell viability was
evaluated by WST-1 assay (Takara, VinciBiochem, Vinci,
Florence, Italy, EU).
As positive and negative controls different concentrations
of 5-FC and 5-FU alone were used in identical in vitro con-
ditions. A cell growth inhibition assay was also used in
order to determine whether the binding with the specific
scFvH5 antibody affects yCD enzyme function.
In this experiment LoVo cells (2500 cells/well) were
seeded in 96-costar plates in BM containing 2.5 μg ml-1 of
yCD and 10 μg ml-1 of 5-FC in presence of scFvH5 or
scFvGO antibodies at concentrations ranging from 0.1 to
10 μg ml-1. All results were represented as the mean of
triplicate samples.
Abbreviations
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